{
  "source": "PA-Notification-Ustekinumab-Stelara.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1097-17\nProgram Prior Authorization/Notification\nMedication *Ustekinumab: **Otulfi® (ustekinumab-aauz), **Pyzchiva®\n(ustekinumab-ttwe), **Selarsdi™ (ustekinumab-aekn), **Stelara®\n(ustekinumab), Steqeyma® (ustekinumab-stba), **Ustekinumab-ttwe,\nWezlana™ (ustekinumab-auub), and Yesintek™ (ustekinumab-kfce)\n*This program applies to the subcutaneous formulation of ustekinumab.\n**Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Selarsdi\n(ustekinumab-aekn), Stelara® (ustekinumab), and Ustekinumab-ttwe\nare excluded from coverage for the majority of our benefits.\nP&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 11/2012, 2/2013, 11/2013, 2/2014, 2/2015, 3/2016,\n11/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021, 12/2021,\n9/2022, 7/2023, 10/2024, 3/2025, 5/2025\nEffective Date 9/15/2025\n1. Background:\nUstekinumab is a human interleukin-12 and -23 antagonist indicated for the treatment of patients\n6 years of age or older with active psoriatic arthritis and for moderate to severe plaque psoriasis\nwho are candidates for phototherapy or systemic therapy. It is also indicated in adult patients\nwith moderately to severely active Crohn’s disease and for moderately to severely active\nulcerative colitis.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Ustekinumab 45 mg/0.5 mL will be approved based on both of the following\ncriteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n©",
    "emfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\nb. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient’s weight is > 100 kg (220 lbs.)\n-AND-\n(3) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab 45 mg/0.5 mL or 90 mg/mL will be approved based on both of the\nfollowing criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Ustekinumab 45 mg/0.5 mL will be approved based on both of the following\ncriteria:\n(1) Diagnosis of active psoriatic arthritis\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination with\nanother targeted immun",
    "ia:\n(1) Diagnosis of active psoriatic arthritis\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination with\nanother targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nb. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient’s weight is > 100 kg (220 lbs.)\n-AND-\n(3) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab 45 mg/0.5 mL or 90 mg/mL will be approved based on both of the\nfollowing criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\nC. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Ustekinumab 90 mg/1 mL will be approved based on both of the",
    "e issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\nC. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Ustekinumab 90 mg/1 mL will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis\n1. Initial Authorization\na. Ustekinumab 90 mg/1 mL will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\n© 2025 UnitedHealthcare Services, Inc.\n4\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (ap",
    "edHealthcare Services, Inc.\n4\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n**Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Selarsdi (ustekinumab-aekn), Stelara\n(ustekinumab), and Ustekinumab-ttwe, are excluded from coverage for the majority of our benefits.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnitedHealthcare Drug Policy for Ustekinumab.\n4. Reference:\n1. Stelara [package insert]. Horsham, PA: Janssen Biotech Inc.; March 2024.\n2. Steqeyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2024.\n3. Yesintek [package insert]. Cambridge, MA: Biocon",
    " [package insert]. Horsham, PA: Janssen Biotech Inc.; March 2024.\n2. Steqeyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2024.\n3. Yesintek [package insert]. Cambridge, MA: Biocon Biologics Inc.; November 2024.\n4. Selarsdi [package insert], Boston, MA: argenx US, Inc.; June 2025.\n5. Otulfi [package insert], Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2024.\n6. Pyzchiva [package insert], Princeton, NJ: Sandoz Inc.; December 2024.\n7. Wezlana [package insert]. Thousand Oaks, CA: Amgen Inc. for Nuvaila; January 2025.\n© 2025 UnitedHealthcare Services, Inc.\n5\nProgram Prior Authorization/Notification - Ustekinumab: **Otulfi\n(ustekinumab-aauz), **Pyzchiva (ustekinumab-ttwe), **Selarsdi\n(ustekinumab-aekn), **Stelara (ustekinumab), Steqeyma (ustekinumab-\nstba), **Ustekinumab-ttwe, Wezlana (ustekinumab-auub), and Yesintek\n(ustekinumab-kfce)\nChange Control\n11/2013 Added criteria for psoriatic arthritis. Extended reauthorization duration\nto 24 months.\n2/2014 Concomitant therapy criterion revised to list most commonly utilized\nbiologic DMARDs. Reauthorization criteria revised to include\nconcomitant therapy criterion.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated background and references.\n3/2016 Annual review. Added Otezla (apremilast) to the combination criteria.\nRemoved co-existent moderate to severe plaque psoriasis from criteria\nto align with the indication section of the prescribing information.\nUpdated statement regarding scope of the program. Added reference to\nUHC drug policy for intravenous infusions. Updated references.\n11/2016 Added criteria for Crohn’s disease. Updated formatting, background\nand references.\n11/2017 Annual review. No changes to program.\n11/2018 Annual review. No changes to clinical coverage criteria. Updated\nbackground and reference.\n11/2019 Updated criteria for Crohn’s disease and new indication for ulcerative\ncolitis. Updated reference.\n11/2020 Annual review. Changed reauthorization ",
    "e criteria. Updated\nbackground and reference.\n11/2019 Updated criteria for Crohn’s disease and new indication for ulcerative\ncolitis. Updated reference.\n11/2020 Annual review. Changed reauthorization durations to 12 months.\nUpdated background and reference.\n11/2021 Annual review with no changes to clinical coverage criteria. Updated\nbackground and reference.\n12/2021 Updated initial authorization for UC to 12 months.\n9/2022 Updated background to include patients 6 years and older with active\npsoriatic arthritis. Added state mandate footnote. Updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n3/2025 Added Steqeyma and Yesintek to all coverage criteria in parity with\nStelara. Updated background and reference.\n5/2025 Renamed program to Ustekinumab. Added Otulfi (ustekinumab-aauz),\nPyzchiva (ustekinumab-ttwe), Selarsdi (ustekinumab-aekn),\nUstekinumab-ttwe, and Wezlana (ustekinumab-auub) to the program.\nAdded notation stating some products are excluded from coverage for\nthe majority of our benefits. Updated Stelara, Steqeyma, or Yesintek to\nUstekinumab throughout the program. Updated references.\n9/5/2025 Administrative change to add Wezlana into coverage.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}